Cargando…
One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
INTRODUCTION: Many patients with von Willebrand disease (VWD) are treated on demand with von Willebrand factor and factor VIII (FVIII) containing concentrates present with VWF and/or FVIII plasma levels outside set target levels. This carries a risk for bleeding and potentially for thrombosis. Devel...
Autores principales: | de Jager, Nico C. B., Bukkems, Laura H., Heijdra, Jessica M., Hazendonk, Carolien H. C. A. M., Fijnvandraat, Karin, Meijer, Karina, Eikenboom, Jeroen, Laros ‐ van Gorkom, Britta A. P., Leebeek, Frank W. G., Cnossen, Marjon H., Mathôt, Ron A. A., Collins, P. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028136/ https://www.ncbi.nlm.nih.gov/pubmed/31557387 http://dx.doi.org/10.1111/jth.14652 |
Ejemplares similares
-
Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018) -
Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021) -
BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019) -
Von Willebrand disease type 2M: Correlation between genotype and phenotype
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2021) -
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)